Teva's Laquinimod Meets Primary Endpoint In First Phase III Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Favorable safety profile may differentiate Teva's laquinimod from competing oral multiple sclerosis therapies.
You may also be interested in...
Teva Extends Diversification To Lobbying, Not Just Product Mix; Seeks To Join BIO
Teva's application to join the Biotechnology Industry Organization may say as much about BIO as it does about the firm.
Teva Extends Diversification To Lobbying, Not Just Product Mix; Seeks To Join BIO
Teva's application to join the Biotechnology Industry Organization may say as much about BIO as it does about the firm.
Despite Short-Term Glitches, Teva Maintains It Is On Track To Double Revenues By 2015
Despite a string of uncharacteristic setbacks, Teva remains confident in its long-term strategy and five-year financial goals it outlined a year ago.